Please login to the form below

Not currently logged in
Email:
Password:

Dr Richard Barker joins Celgene's board of directors

Former ABPI director general takes up second new post this month

Richard Barker - CelgeneFormer director general of the Association of the British Pharmaceutical Industry (ABPI) Dr Richard Barker has been elected to the board of directors at Celgene.

He spent almost seven years at ABPI's helm, stepping down in May last year when he was succeeded by Stephen Whitehead.

It is Barker's second recent appointment after he joined authentication and traceability services company Aegate earlier this month as a senior adviser.

Prior to his post leading the ABPI, Barker's career included serving as chief executive of Chiron Diagnostics, general manager of IBM's Worldwide Healthcare Solutions division and leader of McKinsey & Company's European healthcare practice.

Robert Hugin, Celgene's chairman and CEO, said: “As we continue to expand our global reach, Dr Barker's international perspective will enhance our ability to navigate through an increasingly dynamic healthcare landscape and provide patients access to our innovative therapies.”

The US biopharmaceutical company focuses on developing and commercialising novel treatments for cancer and inflammatory diseases.

Its top-selling product is Revlimid, which suffered a setback last November after a phase III prostate cancer trial found no overall survival benefit.

Nevertheless, the drug is still expected to account for around $3bn of the firm's 2011 sales.

24th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics